NASDAQ:AVTX Avalo Therapeutics Q3 2025 Earnings Report $15.30 -1.21 (-7.33%) Closing price 04:00 PM EasternExtended Trading$15.44 +0.14 (+0.91%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Avalo Therapeutics EPS ResultsActual EPS-$2.19Consensus EPS -$1.67Beat/MissMissed by -$0.52One Year Ago EPSN/AAvalo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAvalo Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsAvalo Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Avalo Therapeutics Earnings HeadlinesAvalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressSeptember 23 at 7:00 AM | globenewswire.comAvalo Therapeutics (NASDAQ:AVTX) CFO Sells $202,394.02 in StockSeptember 21 at 4:22 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 23 at 1:00 AM | Profits Run (Ad)Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Lowered by Wall Street ZenSeptember 12, 2026 | americanbankingnews.comAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comAvalo Therapeutics: Phase 2 Validation Has Created An IL-1β FranchiseSeptember 4, 2026 | seekingalpha.comSee More Avalo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your email. Email Address About Avalo TherapeuticsAvalo Therapeutics (NASDAQ:AVTX) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression. Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation. The company has been evaluating AVTX-009 in inflammatory conditions, including hidradenitis suppurativa, a chronic skin disease. Originally known as Cerecor Inc., the company adopted the Avalo Therapeutics name as it refined its focus on immunology and inflammation. Avalo conducts its development activities primarily in the United States and remains dependent on clinical trials, regulatory approvals and potential partnerships before its investigational therapies can become commercially available.View Avalo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
